Entera Bio Ltd. (ENTX) is a clinical-stage biopharmaceutical company developing orally delivered peptide therapies using its N-Tab platform. It is a stock, not an ETF, and it currently generates no meaningful product revenue, so its valuation rests almost entirely on clinical execution and pipeline optionality.
The $10 central target reflects an arithmetic mean of five recent, attributable analyst targets. Guggenheim initiated coverage with a Buy and an $11.00 target in late September 2026, LifeSci Capital initiated with Outperform and a $10.00 target, Leerink Partners set a $9.00 Outperform target, UBS set a $9.00 target, and H.C. Wainwright reiterated a Buy with a $9.00 target in June 2026. Cantor Fitzgerald also initiated coverage with an Overweight rating, though no standalone target was reported. The resulting range is $9.00 to $11.00, with a calculated mean near $9.60, rounded to $10 for this analysis.
Bullish, neutral, and cautious views differ sharply. Bulls emphasize a de-risked oral PTH (parathyroid hormone) platform and an FDA-supported Phase 3 trial design, while the lone cautious voice (a sell rating) highlights the execution and financing risks typical of pre-revenue biotech. No analyst target is a guarantee, and the wide gap between the current price and these targets reflects high uncertainty.
ENTX has traded in an unusually wide 52-week range of $0.91 to $4.20, and recent quotes have hovered near $2.80 after a period of sharp revaluation. At that level, a move to $10 represents roughly 257% upside, which is a very large move by any standard.
The path toward such a level would almost certainly depend on clinical and regulatory milestones rather than near-term fundamentals. Entera Bio's trailing-twelve-month EPS (earnings per share) is about negative $0.36, with a net loss of roughly $17 million and no product revenue, so valuation would need to be re-rated on catalysts such as Phase 3 progress for EB613 in postmenopausal osteoporosis, updates on EB612 for hypoparathyroidism, or further advancement of its oral GLP-1 obesity program developed with OPKO. A substantial equity raise appears to have already expanded the share count, meaning future appreciation must be shared across a larger base.
ENTX has shown extreme volatility, with a 52-week low of $0.91 and a 52-week high of $4.20. The $4.20 level represents the most recent meaningful overhead resistance, while the low-$2 range has acted as a recurring support zone during pullbacks. A sustained move toward $10 would require first reclaiming and holding above $4.20, a level the stock has not yet broken on a durable basis. These are structural reference points rather than near-term trading signals.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ, and no explicit horizon is uniform across the five targets reviewed. Key items to watch include Phase 3 enrollment and data timelines for EB613, any oral GLP-1 program updates, the next earnings report and cash position disclosure, further financing decisions, and analyst target revisions. Given the binary nature of clinical catalysts, timing estimates should be treated cautiously.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a high-volatility name like ENTX, such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. Traders looking to complement their own research can explore these signals to stay ahead of fast-moving market conditions.
The $10 target for Entera Bio represents a rounded average of five analyst targets spanning $9.00 to $11.00, requiring a roughly 257% rise from a recent price near $2.80. The strongest supports are an FDA-supported Phase 3 osteoporosis design and oral GLP-1 optionality, while the principal obstacles are a pre-revenue model, cash burn, dilution, and binary clinical risk. The unusually wide gap between price and target reflects genuine disagreement about execution rather than consensus conviction. Investors should focus on clinical milestones, financing, and analyst revisions rather than treating $10 as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that ENTX and JSPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and JSPR's prices will move in lockstep.
| Ticker / NAME | Correlation To ENTX | 1D Price Change % | ||
|---|---|---|---|---|
| ENTX | 100% | -0.31% | ||
| JSPR - ENTX | 32% Poorly correlated | -9.90% | ||
| MLTX - ENTX | 30% Poorly correlated | -0.48% | ||
| QCLS - ENTX | 26% Poorly correlated | -6.52% | ||
| NTLA - ENTX | 26% Poorly correlated | -7.76% | ||
| LGVN - ENTX | 25% Poorly correlated | +41.29% | ||
More | ||||